Spark Therapeutics: Gene Therapy For Inherited Retinal Disease – Jay Newman
Jay Newman, Head of U.S. Commercial at Spark Therapeutics provides a detailed overview of gene therapy for inherited retinal disease. Jay discusses the challenges associated with gaining regulatory approval and how this approval has impacted the company and the low vision community at large.
About the guest:
General Manager & Head of US Commercial
Jay Newman has over 30 years of commercial experience in the pharmaceutical and biotech industries. He currently leads all aspects of Spark Therapeutics US Commercial business. As Spark’s Head of US Market Access, Jay envisioned, developed, and directed the execution of Spark’s innovative delivery model entitled SPARK PATHSM in support of LUXTURNA™, the first-ever gene therapy product therapy in the US. SPARK PATH aims to advance patient access to care while balancing the needs of all stakeholders involved in the care-delivery continuum. Previously, he led Biogen’s, payer and channel marketing team which included multiple sclerosis, hemophilia, and rare disease.
Prior to working at Biogen, Jay spent 24 years at Allergan in roles of increasing responsibility in both market access and sales leadership. He led the development of the market access team from a traditional pharmaceutical focus to one responsible for the full Allergan corporate portfolio, which included medical injectable products and devices.
Before his tenure at Allergan, Jay spent five years in the U.S. Army, achieving the rank of Captain. Jay has a bachelor’s degree from Lock Haven University of Pennsylvania and is a two-time finisher of the NYC Marathon with a Personal Best of 3:48:15.